STOCK TITAN

EOM Pharmaceutical Holdings Inc Stock Price, News & Analysis

IMUC OTC

Welcome to our dedicated page for EOM Pharmaceutical Holdings news (Ticker: IMUC), a resource for investors and traders seeking the latest updates and insights on EOM Pharmaceutical Holdings stock.

Immunocellular Therapeutics, Ltd. (IMUC) is a clinical-stage biotech company pioneering dendritic cell immunotherapies for aggressive cancers. This page aggregates official updates on their glioblastoma treatment ICT-107, ovarian cancer program ICT-140, and stem cell engineering research.

Investors and researchers will find verified updates on clinical trial progress, regulatory milestones, and scientific collaborations. Our curated feed includes press releases about treatment efficacy data, patent developments, and partnership announcements.

All content is sourced directly from company filings and peer-reviewed publications. Bookmark this page for structured access to IMUC's cancer vaccine developments, including the CD133-targeting ICT-121 program and hematopoietic stem cell research updates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
clinical trial covid-19
-
Rhea-AI Summary

EOM Pharmaceuticals, Inc. and ImmunoCellular Therapeutics have completed a merger, making EOM shareholders the majority owners of the combined entity. The merger aims to advance EOM's pipeline, focusing on immunomodulatory agents and retinal disease therapies. The new company will be known as EOM Pharmaceuticals Holdings, Inc., while the existing common stock will continue to trade under the ticker symbol IMUC until a new symbol is assigned. EOM613 and EOM147 are the key pipeline assets targeting severe COVID-19 and retinal diseases respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.65%
Tags
Rhea-AI Summary

ImmunoCellular Therapeutics (OTC: IMUC) announced compliance steps for the amended Rule 15c2-11 of the Securities and Exchange Act, effective September 2021. The company has submitted an application to the OTC and intends to submit unaudited financial statements by the compliance deadline of June 30, 2021. Non-compliance would result in loss of public trading eligibility for its common stock. This proactive measure aims to ensure transparency and maintain investor confidence ahead of the regulatory changes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
none

FAQ

What is the current stock price of EOM Pharmaceutical Holdings (IMUC)?

The current stock price of EOM Pharmaceutical Holdings (IMUC) is $0.1043 as of June 20, 2025.

What is the market cap of EOM Pharmaceutical Holdings (IMUC)?

The market cap of EOM Pharmaceutical Holdings (IMUC) is approximately 19.1M.
EOM Pharmaceutical Holdings Inc

OTC:IMUC

IMUC Rankings

IMUC Stock Data

19.12M
5.70M
94.97%
3.96%
Biotechnology
Healthcare
Link
United States
Montvale